Bioline Rx Ltd
Research Bioline Rx Ltd (BLRX) on Bullrun: market cap USD 9.70M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBLRX
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 9.70M
- Financial periodQ2 2026
- RevenueUSD 294.00K
- Net income-USD 3.03M
- Free cash flow-USD 3.21M
- Gross margin79.9%
Valuation Snapshot
latest market cap is USD 9.70M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.18M | -USD 1.18M | -USD 8.10M | 80.5% | 0 | USD 3.25M | USD 10.15M | USD 18.20M |
| FY2024 | USD 28.94M | -USD 9.22M | -USD 43.93M | 68.0% | -6 | USD 10.44M | USD 15.04M | USD 13.46M |
| FY2023 | USD 4.80M | -USD 60.61M | -USD 22.91M | 23.1% | -36 | USD 4.26M | USD 11.59M | USD 13.22M |
| FY2022 | USD 0 | -USD 24.95M | -USD 26.56M | n/a | -18 | USD 10.59M | USD 12.32M | USD 50.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 9.70M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 12.05M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.71M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 113.73M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 36.30M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 97.26M | n/a | n/a | n/a |
About Bioline Rx Ltd
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Bioline Rx Ltd's market cap?
Bioline Rx Ltd's market capitalization is USD 9.70M.
What does Bioline Rx Ltd do?
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.